After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...

The news: CSL has committed to a USD1.5 billion ($2.12 billion) expansion of its Illinois plasma therapy manufacturing facility, which it broke ground on Monday. The numbers: The Kankakee facility ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CSL has started construction ...

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. CSL and Eli Lilly have struck a strategic ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

It's been a sad week for CSL Limited (ASX:CSL), who've watched their investment drop 16% to AU$152 in the week since the company reported its interim result. Revenues came in 2.7% below expectations, ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

CSL has dumped chief executive Paul McKenzie after a brutal year for the global biotechnology giant, installing a former senior manager as interim boss following pressure from shareholders for a ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

The news: Embattled biotech giant CSL has announced the retirement of CEO and managing director Paul McKenzie, effective today. CSL senior executive and non-executive director Gordon Naylor has been ...